{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:37:18Z","timestamp":1790649438628,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.494900\/2020-00"],"award-info":[{"award-number":["88887.494900\/2020-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.518214\/2020-00"],"award-info":[{"award-number":["88887.518214\/2020-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["SGPP 3563-18"],"award-info":[{"award-number":["SGPP 3563-18"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["420883\/2018-5"],"award-info":[{"award-number":["420883\/2018-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jim.2023.113441","type":"journal-article","created":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T12:18:25Z","timestamp":1677413905000},"page":"113441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["In vitro differentiation of myeloid suppressor cells (MDSC-like) from an immature myelomonocytic precursor THP-1"],"prefix":"10.1016","volume":"515","author":[{"given":"Vanessa Ara\u00fajo","family":"Varela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia Borges","family":"da Silva Heinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Cavalheiro","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vict\u00f3ria Bulc\u00e3o","family":"Caraciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarcila Santos","family":"Datoguia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane Tami","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Welbert Oliveira","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2023.113441_bb0005","first-page":"1055","article-title":"Glycolytic, glutaminolytic and pentose-phosphate pathways in promyelocytic HL60 and DMSO-differentiated HL60 cells","volume":"29","author":"Ahmed","year":"1993","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/j.jim.2023.113441_bb0010","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","article-title":"Macrophage-based approaches for cancer immunotherapy","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2023.113441_bb0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF02041244","article-title":"The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation","volume":"47","author":"Auwerx","year":"1991","journal-title":"Experientia"},{"key":"10.1016\/j.jim.2023.113441_bb0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.leukres.2007.04.013","article-title":"All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias","volume":"32","author":"Barber","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jim.2023.113441_bb0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.coi.2018.03.015","article-title":"Plasticity and biological diversity of myeloid derived suppressor cells","volume":"51","author":"Ben-Meir","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0030","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1134\/S0006297919110129","article-title":"Conditioned medium of mesenchymal stromal cells: a new class of therapeutics","volume":"84","author":"Bogatcheva","year":"2019","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.jim.2023.113441_bb0035","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.humimm.2016.05.024","article-title":"Myeloid derived suppressor cells and autoimmunity","volume":"77","author":"Boros","year":"2016","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0040","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jim.2023.113441_bb0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00262-018-2170-8","article-title":"How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions","volume":"68","author":"Bruger","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jim.2023.113441_bb0050","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3389\/fimmu.2019.00771","article-title":"Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression","volume":"10","author":"Bruno","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001223","article-title":"Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation","volume":"8","author":"Cassetta","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jim.2023.113441_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.intimp.2014.08.002","article-title":"THP-1 cell line: an in vitro cell model for immune modulation approach","volume":"23","author":"Chanput","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jim.2023.113441_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jim.2023.113441_bb0070","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.intimp.2011.01.026","article-title":"MDSC in autoimmunity","volume":"11","author":"Cripps","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jim.2023.113441_bb0075","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/9\/1\/015006","article-title":"3D bioprinting of functional human skin: production and in vivo analysis","volume":"9","author":"Cubo","year":"2016","journal-title":"Biofabrication"},{"key":"10.1016\/j.jim.2023.113441_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cytob.21206","article-title":"Complexity and challenges in defining myeloid-derived suppressor cells","volume":"88","author":"Damuzzo","year":"2015","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.jim.2023.113441_bb0085","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","article-title":"CAR-T cells: early successes in blood cancer and challenges in solid tumors","volume":"11","author":"Dana","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jim.2023.113441_bb0090","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1002\/ajh.25416","article-title":"CARs of the future","volume":"94","author":"Daniyan","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jim.2023.113441_bb0095","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jcyt.2014.03.009","article-title":"Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease","volume":"16","author":"Davies","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jim.2023.113441_bb0100","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3389\/fimmu.2020.01680","article-title":"The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1196312","article-title":"Improving cancer immunotherapy by targeting the STATe of MDSCs","volume":"5","author":"de Haas","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jim.2023.113441_bb0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40259-021-00477-8","article-title":"CAR-T cell therapy for acute myeloid leukemia: preclinical rationale, current clinical progress, and barriers to success","volume":"35","author":"Fiorenza","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.jim.2023.113441_bb0115","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.1252510","article-title":"The cellular and molecular origin of tumor-associated macrophages","volume":"344","author":"Franklin","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jim.2023.113441_bb0120","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0125","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/0008-5472.CAN-06-3037","article-title":"The terminology issue for myeloid-derived suppressor cells","volume":"67","author":"Gabrilovich","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2023.113441_bb0130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0135","article-title":"Immunotherapy targeting myeloid-derived suppressor cells (MDSCs) in tumor microenvironment","volume":"11","author":"Gao","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0140","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1186\/s12885-015-1546-9","article-title":"M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide","volume":"15","author":"Genin","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jim.2023.113441_bb0145","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2174\/156800911796191024","article-title":"Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer","volume":"11","author":"Goedegebuure","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jim.2023.113441_bb0150","article-title":"Quantification of RNA by real-time reverse transcription-polymerase chain reaction (RT-PCR)","volume":"2018","author":"Green","year":"2018","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.jim.2023.113441_bb0155","series-title":"Biofabrication","article-title":"A definition of bioinks and their distinction from biomaterial inks","volume":"vol. 11","author":"Groll","year":"2019"},{"key":"10.1016\/j.jim.2023.113441_bb0160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3892\/etm.2021.9784","article-title":"Differentiation of HL-60 cells in serum-free hematopoietic cell media enhances the production of neutrophil extracellular traps","volume":"21","author":"Guo","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.jim.2023.113441_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071568","article-title":"Realizing innate potential: CAR-NK cell therapies for acute myeloid leukemia","volume":"13","author":"Gurney","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jim.2023.113441_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212200","article-title":"3D cell culture systems: tumor application, advantages, and disadvantages","volume":"22","author":"Habanjar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jim.2023.113441_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jim.2023.113441_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.05.002","article-title":"Cellular therapy for acute myeloid leukemia - current status and future prospects","volume":"37","author":"Hansrivijit","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.jim.2023.113441_bb0185","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1101\/gr.6.10.986","article-title":"Real time quantitative PCR","volume":"6","author":"Heid","year":"1996","journal-title":"Genome Res."},{"key":"10.1016\/j.jim.2023.113441_bb0190","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1295203","article-title":"Generation and functional characterization of MDSC-like cells","volume":"6","author":"Heine","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jim.2023.113441_bb0195","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev.med.59.061506.154239","article-title":"Mesenchymal stem cells in acute kidney injury","volume":"59","author":"Humphreys","year":"2008","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jim.2023.113441_bb0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00005-017-0492-4","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: current knowledge and future perspectives","volume":"66","author":"Ib\u00e1\u00f1ez-Vea","year":"2018","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.jim.2023.113441_bb0205","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.3892\/mmr.2016.5685","article-title":"Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules","volume":"14","author":"Ilkovitch","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jim.2023.113441_bb0210","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10555-019-09834-0","article-title":"Immunotherapy in pediatric acute lymphoblastic leukemia","volume":"38","author":"Inaba","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jim.2023.113441_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.656218","article-title":"Immunotherapy in acute myeloid leukemia: where we stand","volume":"11","author":"Isidori","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jim.2023.113441_bb0220","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13287-022-02941-w","article-title":"Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I\/II randomized placebo-controlled clinical trial","volume":"13","author":"Izadi","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jim.2023.113441_bb0225","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jim.2023.113441_bb0230","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12956","article-title":"Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis","volume":"54","author":"Jiang","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.jim.2023.113441_bb0235","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nbt.3413","article-title":"A 3D bioprinting system to produce human-scale tissue constructs with structural integrity","volume":"34","author":"Kang","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jim.2023.113441_bb0240","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jim.2023.113441_bb0245","doi-asserted-by":"crossref","first-page":"12307","DOI":"10.1038\/s41598-018-29968-5","article-title":"3D bioprinted human skeletal muscle constructs for muscle function restoration","volume":"8","author":"Kim","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jim.2023.113441_bb0250","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jim.2023.113441_bb0255","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.jim.2023.113441_bb0260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fonc.2017.00022","article-title":"Overview of the use of murine models in leukemia and lymphoma Research","volume":"7","author":"Kohnken","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jim.2023.113441_bb0265","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2174\/0929867311320110006","article-title":"Myeloid derived suppressor cells and their role in diseases","volume":"20","author":"Kong","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jim.2023.113441_bb0270","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/bioinformatics\/btm091","article-title":"Enhancements and modifications of primer design program Primer3","volume":"23","author":"Koressaar","year":"2007","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jim.2023.113441_bb0275","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jim.2012.04.004","article-title":"Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples","volume":"381","author":"Kotsakis","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2023.113441_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051170","article-title":"Immunosuppressive effects of myeloid-derived suppressor cells in cancer and immunotherapy","volume":"10","author":"Krishnamoorthy","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jim.2023.113441_bb0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00262-005-0048-z","article-title":"Role of immature myeloid cells in mechanisms of immune evasion in cancer","volume":"55","author":"Kusmartsev","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jim.2023.113441_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030561","article-title":"Myeloid-derived suppressor cells as a therapeutic target for cancer","volume":"9","author":"Law","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jim.2023.113441_bb0295","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.4049\/jimmunol.1000901","article-title":"Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells","volume":"185","author":"Lechner","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0300","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-05-4005","article-title":"Distinct role of macrophages in different tumor microenvironments","volume":"66","author":"Lewis","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2023.113441_bb0305","article-title":"Mesenchymal stem cell therapy: hope for patients with systemic lupus erythematosus","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0310","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2023.113441_bb0315","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-019-0797-3","article-title":"Myeloid-derived suppressor cells in hematological malignancies: friends or foes","volume":"12","author":"Lv","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jim.2023.113441_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/cells11020310","article-title":"Myeloid-derived suppressor cells in solid tumors","volume":"11","author":"Ma","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jim.2023.113441_bb0325","doi-asserted-by":"crossref","first-page":"13532","DOI":"10.1038\/s41598-018-31848-x","article-title":"A multi-cellular 3D bioprinting approach for vascularized heart tissue engineering based on HUVECs and iPSC-derived cardiomyocytes","volume":"8","author":"Maiullari","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jim.2023.113441_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108452","article-title":"Role of myeloid derived suppressor cells in sepsis","volume":"104","author":"Malavika","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jim.2023.113441_bb0335","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/imcb.12015","article-title":"The influence of agents differentiating HL-60 cells toward granulocyte-like cells on their ability to release neutrophil extracellular traps","volume":"96","author":"Manda-Handzlik","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jim.2023.113441_bb0340","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0167-5699(92)90008-U","article-title":"The origin and function of tumor-associated macrophages","volume":"13","author":"Mantovani","year":"1992","journal-title":"Immunol. Today"},{"key":"10.1016\/j.jim.2023.113441_bb0345","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T cells for acute myeloid leukemia: state of the art and future directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jim.2023.113441_bb0350","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.immuni.2010.05.010","article-title":"Tumor-induced tolerance and immune suppression depend on the C\/EBPbeta transcription factor","volume":"32","author":"Marigo","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jim.2023.113441_bb0355","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2023.113441_bb0360","first-page":"1","article-title":"Cutting to the front of the line: immunotherapy for childhood acute lymphoblastic leukemia","volume":"40","author":"McNeer","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.jim.2023.113441_bb0365","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0370","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.18632\/oncotarget.12278","article-title":"On the origin of myeloid-derived suppressor cells","volume":"8","author":"Millrud","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jim.2023.113441_bb0375","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.jim.2023.113441_bb0380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jim.2023.113441_bb0385","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1158\/0008-5472.CAN-05-0529","article-title":"Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2\/signal transducers and activators of transcription 3 pathway","volume":"65","author":"Nefedova","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2023.113441_bb0390","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s10787-021-00846-3","article-title":"Role of myeloid-derived suppressor cell (MDSC) in autoimmunity and its potential as a therapeutic target","volume":"29","author":"Nourbakhsh","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.jim.2023.113441_bb0395","doi-asserted-by":"crossref","first-page":"F6","DOI":"10.1152\/ajprenal.00341.2015","article-title":"Mesenchymal stem cells and chronic renal artery stenosis","volume":"310","author":"Oliveira-Sales","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.jim.2023.113441_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078464","article-title":"Mesenchymal stem cells (MSC) prevented the progression of renovascular hypertension, improved renal function and architecture","volume":"8","author":"Oliveira-Sales","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jim.2023.113441_bb0405","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jim.2023.113441_bb0410","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","article-title":"Myeloid-derived suppressor cells: linking inflammation and cancer","volume":"182","author":"Ostrand-Rosenberg","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0415","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression","volume":"22","author":"Ostrand-Rosenberg","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jim.2023.113441_bb0420","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jim.2023.113441_bb0425","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","article-title":"NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors","volume":"7","author":"Parihar","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jim.2023.113441_bb0430","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","article-title":"Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment","volume":"128","author":"Parker","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.jim.2023.113441_bb0435","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.18632\/oncotarget.6662","article-title":"Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression","volume":"7","author":"Pinton","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jim.2023.113441_bb0440","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3389\/fimmu.2019.00774","article-title":"Complementing the cancer-immunity cycle","volume":"10","author":"Pio","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0445","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clim.2012.06.003","article-title":"On the armament and appearances of human myeloid-derived suppressor cells","volume":"144","author":"Poschke","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0450","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17186","article-title":"Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity","volume":"193","author":"Rafei","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jim.2023.113441_bb0455","first-page":"71","article-title":"An improvement of the 2\u02c6(\u2212delta delta CT) method for quantitative real-time polymerase chain reaction data analysis","volume":"3","author":"Rao","year":"2013","journal-title":"Biostat. Bioinforma. Biomath."},{"key":"10.1016\/j.jim.2023.113441_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044092","article-title":"Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats","volume":"7","author":"Reis","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jim.2023.113441_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104302","article-title":"Myeloid-derived suppressor cells (MDSC): when good intentions go awry","volume":"362","author":"Sanchez-Pino","year":"2021","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0470","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111592","article-title":"Mesenchymal stem cell-based therapy for rheumatoid arthritis","volume":"22","author":"Sarsenova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jim.2023.113441_bb0475","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/jlb.59.4.555","article-title":"Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3","volume":"59","author":"Schwende","year":"1996","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jim.2023.113441_bb0480","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13287-016-0341-0","article-title":"Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015)","volume":"7","author":"Singh","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jim.2023.113441_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-macrophages as adoptive immunotherapies for solid tumors","volume":"12","author":"Sloas","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0490","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jim.2023.113441_bb0495","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2010-12-325753","article-title":"A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells","volume":"118","author":"Solito","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jim.2023.113441_bb0500","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/nyas.12469","article-title":"Myeloid-derived suppressor cell heterogeneity in human cancers","volume":"1319","author":"Solito","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jim.2023.113441_bb0505","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.990463","article-title":"Immunotherapy of targeting MDSCs in tumor microenvironment","volume":"13","author":"Sui","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0510","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","article-title":"Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia","volume":"102","author":"Sun","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jim.2023.113441_bb0515","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jim.2023.113441_bb0520","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1182\/bloodadvances.2020003844","article-title":"Tisagenlecleucel immunogenicity in relapsed\/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"5","author":"Thudium Mueller","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.jim.2023.113441_bb0525","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jim.2023.113441_bb0530","article-title":"The role of myeloid-derived suppressor cells (MDSC) in cancer progression","volume":"4","author":"Umansky","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jim.2023.113441_bb0535","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gks596","article-title":"Primer3\u2013new capabilities and interfaces","volume":"40","author":"Untergasser","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jim.2023.113441_bb0540","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1159\/000503346","article-title":"Treatment with mesenchymal stem cells improves renovascular hypertension and preserves the ability of the contralateral kidney to excrete sodium","volume":"44","author":"Varela","year":"2019","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.jim.2023.113441_bb0545","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0550","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-065X.2006.00437.x","article-title":"TGF-beta: a mobile purveyor of immune privilege","volume":"213","author":"Wahl","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jim.2023.113441_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104254","article-title":"IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy","volume":"359","author":"Weber","year":"2021","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jim.2023.113441_bb0560","doi-asserted-by":"crossref","first-page":"36663","DOI":"10.1038\/srep36663","article-title":"Inhibiting MDSC differentiation from bone marrow with phytochemical polyacetylenes drastically impairs tumor metastasis","volume":"6","author":"Wei","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jim.2023.113441_bb0565","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1158\/0008-5472.CAN-05-3755","article-title":"CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2023.113441_bb0570","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200111","article-title":"Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine","volume":"10","author":"Yaseen","year":"2020","journal-title":"Open Biol."},{"key":"10.1016\/j.jim.2023.113441_bb0575","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-020-00998-9","article-title":"Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy","volume":"13","author":"Yilmaz","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jim.2023.113441_bb0580","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/0008-5472.CAN-04-4505","article-title":"Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion","volume":"65","author":"Zea","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2023.113441_bb0585","article-title":"3D bioprinting of human tissues: biofabrication, bioinks, and bioreactors","volume":"22","author":"Zhang","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175923000236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175923000236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:28:30Z","timestamp":1762205310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175923000236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":117,"alternative-id":["S0022175923000236"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2023.113441","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro differentiation of myeloid suppressor cells (MDSC-like) from an immature myelomonocytic precursor THP-1","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2023.113441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113441"}}